• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$33.09 $0.10 (0.30%)

REAL-TIME: Last trade at

Bristol-Myers Squibb Co.

NYSE:BMY

Is This Biotech's Best Stock?

5 Stable Stocks For The Ideal Dividend Portfolio

Have J&J's Approval Hopes Vanished?

The Dow's 3 Biggest Losers This Week

Mylan Launches Bonviva Generic - Analyst Blog

'Buy Zones' For The DIY Dividend Portfolio Part 3b: Healthcare

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3

Johnson & Johnson: An Uncommon Opportunity

Johnson & Johnson Setback Is Positive for Pfizer, Bristol-Myers

4 Large Cap Dividend Stocks With Strong Profits That Analysts Rate As Buy

FDA Nod for Merck Drug Label Update - Analyst Blog

More Generic Launches for Mylan - Analyst Blog

Finding a Pathway to Approval

JNJ Updates: Imodium Recalls; Heading For Chinese Acquisitions; Zytiga’s Success

JNJ Updates: Positives For Xarelto & Simponi

Are 3 Failed Phase 3 Trials Enough?

Is Bristol a Buy Post-Plavix

The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr.

How to Play an Arena Delay

Too Little, Too Late for Achillion?

UPDATE: FDA Reviewer Backs Expanded Approval Of Bayer, J&J's Xarelto

RDY Adds to Generic Portfolio - Analyst Blog

Generic Launches Continue at Mylan - Analyst Blog

Johnson & Johnson's Xarelto Should Be Given to More Patients, FDA Staff Says

Bristol-Myers Squibb's Thud Heard Round the World

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP

Dr. Reddy's Launches Plavix' Generic - Analyst Blog

Merck KGaA's Erbitux Faces Hurdle - Analyst Blog

5 Pharmaceutical Stocks With Significant Exposure to Europe

UPDATE:FDA Approves Generic Versions Of Blood-Thinning Drug Plavix

FDA Approves Generic Versions Of Blood Thinning Drug Plavix

Manufacturing Facility Cleared at BMY - Analyst Blog

2 Reasons That Cystic Fibrosis Trumps Hep C

Has Ariad Pharmaceuticals Become the Perfect Stock?

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation,

BMY Inks Deal with Chinese University - Analyst Blog

This Biotech's for Sale! Reportedly.

HIV Drug Maker Gilead Sciences Scores Two Wins

Good News for Gilead - Analyst Blog

A Step Closer to Quadrific Sales

See More Articles...